Sotatercept trial for children with pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child already has a confirmed PAH diagnosis from a heart test called a right heart catheterization (RHC).
- The PAH type fits one of these: idiopathic, inherited (heritable), caused by medicines/toxins, related to connective tissue disease, or certain congenital heart-related PAH cases.
- Your child must be on a stable PAH treatment plan (such as PDE5 inhibitors, endothelin receptor blockers, soluble guanylate cyclase stimulators, or prostanoids) before starting.
- There must be no major heart-side problems (like significant valve disease or left heart failure).
- There must not be certain lung/heart conditions (for example, Eisenmenger syndrome, unrepaired shunts, lung blood-vessel blocking diseases, or certain lung development problems).
- Your child (or you, if applicable) must follow strict pregnancy prevention and blood/donation rules during the study and for 16 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This study tests whether people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, can safely stop taking the medication sotatercept after being on it for at least 6 months and doing well. It aims to see if those who stop can maintain their health without the drug.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.